Анализ изменений аномального метилирования ДНК в процессе комплексного лечения при остром миелоидном лейкозе у детей

Viktoria V. Rudenko, Svetlana Kazakova, Alexander S. Tanas et al. · Medical genetics (Research Centre of Medical Genetics of the Russian Academy of Medical Sciences) · 2018

An aberrant DNA methylation distribution is a functional event in the process of leukemogenesis and a target of epigenetic therapy. To identify DNA methylation markers most common for any molecular subtype of pediatric acute myeloid leukemia (AML) we have applied a method of unbiased differential methylation screening of the genomes and designed  multiplex MS-PCR system of DNA methylation markers belonging to the promoter regions of the genes  EGFLAM, TMEM176A/176B, GSG1L, CLDN7, CXCL14 and SOX8. The system has a sensitivity of 90—91% for determining the malignant process. We have studied bone marrow samples  from 39 children with AML. All patients were treated by decitabine and ATRA in complex with chemotherapy (CT). Methylation index (MI) was 0.197 ± 0.181 for patients with a myeloblasts content less than 40%, and 0.514 ± 0.222 for patients with myeloblasts content more than 40% (p = 0.000736). Methylation of the CLDN7, GSGL1 and EGFLAM genes is absent  in the group with low MI. Patients with the initial content of myeloblasts less than 40% demonstrate absence of methylation on the 15th day after the start of the CT. The average MI decreases in the group with the initially high content of myeloblasts due to decrease in the frequencies of methylation of the genes CXCL14, TMEM176A/176B, GSGL1 and SOX8. The 5-day course  of demethylation therapy is accompanied by an increase in the content of blast cells and an equalization of the methylation profile. With the marker system developed it is possible to evaluate the malignant progression of blast cells, which are considered morphologically normal after CT, demonstrating at the same time the abnormal methylation profile of tumor cells.

Cited by 0 works. doi:10.25557/2073-7998.2018.07.21-29

Authors